ORION CORPORATION STOCK EXCHANGE RELEASE 30 NOVEMBER 2012 at 1:10 PM EET
Orion Corporation is developing a budesonide-formoterol formulation combining budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler® drug product family for treatment of asthma and COPD.
Based on the favorable pharmacokinetic study results of this Easyhaler-development programme Orion is planning to apply for a marketing authorisation for the combined budesonide-formoterol formulation. Orion currently estimates that the marketing authorisation application would be submitted in Europe during the first half of 2013.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact persons:
Reijo Salonen, Senior Vice President, Research and Development (as of Monday 3 December)
tel. +358 50 966 3647
Jari Karlson, CFO
tel. +358 50 966 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi (http://www.orion.fi)
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
